CAS: 204005-46-9; 3-((3,5-Dimethyl-1H-Pyrrol-2-yl)Methylene)Indolin-2-One

该化合物是一个小分子,主要作为某些动脉酶的选择性抑制器,尤其是那些涉及癌症细胞扩散和生存的动脉,其特征是能够干扰特定的信号路径,使其成为定向癌症疗法的候选对象.Semaxinib展示了一种有利的药用动能特征,包括良好的口服生物利用率和有效组织分布的潜力.该化合物在各种临床前模型中被研究过,显示出抑制肿瘤生长和转移的能力.此外,Semaxinib的行动机制涉及调节诸如流行性疾病和血管生成等细胞过程,这些过程对于癌症的演变至关重要.其发展是创建更有效,毒性更低的癌症治疗方法,重点是精密药物方法的更广泛努力的一部分.随着研究的继续,Semaxinib的全部治疗潜力和安全特征正在临床环境中评估.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号2199-58-8 3,5-二甲基-2-吡咯甲醛 | CAS号59-48-3 2-吲哚酮

合成工艺路线路线简述

    📜3,5-二甲基-2-吡咯甲醛,2-吲哚酮置于哌啶 乙醇体系中,用 乙醇 用作溶剂,化学反应 3.0H,以to Yield 136.7 Mg (57%) Of The Title Compound As A Yellow Solid的收率获得1,3-二氢-3-[(3,5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮
    参考文献:3-(4'-Bromobenzylindenyl)-2-Indolinone And Analogues Thereof For The
    标题:3-(4'-Bromobenzylindenyl)-2-Indolinone And Analogues Thereof For The
    摘要:本发明涉及有机分子,能够调节酪氨酸激酶信号转导,以调节,调控和/或抑制异常细胞增殖.

    海关参考信息

    专利信息


    专利号:US-8598153-B2
    优先权日:2006-09-22
    标题 :Method of treatment using fatty acid synthesis inhibitors
    发明人：SINGH SHEO B; TOTA MICHAEL R; WANG JUN
    权利人:SINGH SHEO B; TOTA MICHAEL R; WANG JUN; MERCK SHARP & DOHME
    摘要:The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.

    专利号:WO-9948868-A9
    优先权日:1998-03-26
    标 题 :Heterocyclic classes of compounds for the modulating tyrosine protein kinase
    发明人：FONG ANNIE; HANNAH ALISON; HARRIS G DAVIS; HIRTH PETER; HUBBARD STEVEN R; LANGECKER PETER; LIANG CONGXIN; MCMAHON GERALD; MOHAMMADI MOOSA; SCHLESSINGER JOSEPH; SHAWVER LAURA K; SUN LI; TANG PENG C; ULLRICH AXEL
    权利人:SUGEN INC; UNIV NEW YORK; MAX PLANCK INST FUR BIOCHEMIE; FONG ANNIE; HANNAH ALISON; HARRIS G DAVIS; HIRTH PETER; HUBBARD STEVEN R; LANGECKER PETER; LIANG CONGXIN; MCMAHON GERALD; MOHAMMADI MOOSA; SCHLESSINGER JOSEPH; SHAWVER LAURA K; SUN LI; TANG PENG C; ULLRICH AXEL
    摘要:The invention relates to certain indolinone-based and pyrazolylamide-based compounds, their method of synthesis, and combinatorial libraries consisting of the compounds. The invention also relates to methods of modulating the function of protein kinases using these compounds and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

    专利号:US-2006205787-A1
    优先权日:2005-01-25
    标题 :Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione
    发明人：MULLER GEORGE W; CHEN ROGER S
    权利人:MULLER GEORGE W; CHEN ROGER S
    摘要:This invention relates to racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof. Synthesis, methods of use, and pharmaceutical compositions of racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxo-piperidine-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof, are disclosed.

    专利号:AU-2007300627-A1
    优先权日:2006-09-22
    标题:Method of treatment using fatty acid synthesis inhibitors

    专利号:AU-2007300627-B2
    优先权日:2006-09-22
    标题 :Method of treatment using fatty acid synthesis inhibitors

    专利号:JP-2010504329-A
    优先权日:2006-09-22
    标题:Methods of treatment using fatty acid synthesis inhibitors

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kwon H, Lee JH, Yoo JM, Nguyen H, An H, Chang SE, Song Y. Semaxanib, a VEGF inhibitor, suppresses melanogenesis by modulating CRTC3 independently of VEGF signaling. J Dermatol Sci. 2024 Sep;115(3):121-129. doi: 10.1016/j.jdermsci.2024.07.004. Epub 2024 Jul 22. 19(2):238-250. doi: 10.4103/RPS.RPS_244_22.
    3: Peng K, Xie W, Wang T, Li Y, de Dieu Habimana J, Amissah OB, Huang J, Chen Y, Ni B, Li Z. HIF-1α promotes kidney organoid vascularization and applications in disease modeling. Stem Cell Res Ther. 2023 Nov 19;14(1):336. doi: 10.1186/s13287-023-03528-9.
    4: Xu W, Xu X, Yao L, Xue B, Xi H, Cao X, Piao G, Lin S, Wang X. VEGFA-modified DPSCs combined with LC-YE-PLGA NGCs promote facial nerve injury repair in rats. Heliyon. 2023 Mar 28;9(4):e14626. doi: 10.1016/j.heliyon.2023.e14626.

    合成参考文献


    参考文献:10.1016/j.tiv.2005.06.047
    摘要:Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie B, Parkinson A, Antonian L. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol In Vitro. 2006 Mar;20(2):154–62. doi: 10.1016/j.tiv.2005.06.047.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知